Atazanavir: The Advent of a New Generation of More Convenient Protease Inhibitors

REFERENCES

• van Leth F, Andrews S, Grinsztijen B, et al. Virologic failure in antiretroviral therapy-naïve patients is only de-termined by extreme low values of CD4+ cells or high values of HIV-RNA concentration, not by choice of treat-ment with nevirapine or efavirenz. In: Program and ab-stracts of the 11th Conference on Retroviruses and Op-portunistic Infections; 2004; San Francisco. Abstract 550.
   Google Scholar
• Hoogewerf M, Regez R, Schouten W, et al. Change to abacavir-lamivudine-tenofovir combination treatment in patients with HIV-1 who had complete virological sup-pression. Lancet. 2003;362:1979–1980.
   PubMed Web of Science ®Google Scholar
• Martinez E, Arnaiz J, Podzamczer D, et al. Substitution of nevirapine, efavirenz or abacavir for protease inhibitors in patients with HIV infection. N Engl J Med. 2003; 349:1036–1046.
   PubMed Web of Science ®Google Scholar
• Barreiro P, Camino N, de Mendoza C, et al. Comparison of the efficacy, safety, and predictive value of HIV genotyping using distinct ritonavir-boosted protease in-hibitors. Int J Antimicrob Agents. 2002;20:438–443.
   PubMed Web of Science ®Google Scholar
• Piliero P. Atazanavir: a novel HIV-1 protease inhibitor. Expert Opin Invest Drugs. 2002;11:1295–1301.
   PubMed Web of Science ®Google Scholar
• Robinson B, Riccardi K, Gong Y, et al. BMS-232632, a highly potent HIV protease inhibitor that can be used in combination with the available antiretroviral agents. Antimicrob Agents Chemother. 2000;44:2093–2099.
   PubMed Web of Science ®Google Scholar
• Roberts N, Martin J, Kinchington D, et al. Rational design of peptide based HIV proteinase inhibitors. Science. 1990;248:358–361.
   PubMed Web of Science ®Google Scholar
• Gong Y, Robinson B, Rose R, et al. In vitro resistance profile of HIV-1 protease inhibitor BMS-232632. Antimicrob Agents Chemother. 2000;44:2319–2326.
   PubMed Web of Science ®Google Scholar
• Colonno R, Thiry A, Limoli K, et al. Activities of atazanavir against a large panel of HIV type 1 clinical isolates resis-tant to one or more approved protease inhibitors. Antimicrob Agents Chemother. 2003;47:1324–1333.
   PubMed Web of Science ®Google Scholar
• Witherell G. BMS-232632. Curr Opin Inyestig Drugs. 2001;2:340–347.
   PubMedGoogle Scholar
• Randall D, Agarwala S, Mummaneni V, et al. Tissue com-partment concentrations of atazanavir in cerebrospinal fluid, seminal fluid and plasma in HIV+ subjects. In: Pro-gram and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27–30, 2002; San Diego, CA. Abstract 273.
   Google Scholar
• O'Mara E, Piliero P, Drusano G, et al. A preliminary phar-macokinetic and pharmacodynamic evaluation of BMS-232632 in protease inhibitor-naïve HIV+ population. AIDS. 2000;14:519.
   Web of Science ®Google Scholar
• Colonno R, Rose R, McLaren C, et al. Identification of 150L as the signature atazanavir-resistance mutation in treatment-naïve HIV-infected patients receiving atazanavir-containing regimens. J Infect Dis. 2004; 189:18002–18010.
   Web of Science ®Google Scholar
• Seekins D, Parkin N, Chappey C, et al. Impact of residue 50 substitutions on phenotypic susceptibility to protease inhibitors. In: Program and abstracts of the XIII Interna-tional HIV Drug Resistance Workshop; June 8–11, 2004; Tenerife, Spain. Abstract 18.
   Google Scholar
• Colonno R, Thiry A, Parkin N. Amino acid substitutions that correlate with decreased susceptibility of atazanavir and other HIV-1 protease inhibitors. In: Program and abstracts of the 42nd Interscience Conference on Antimi-crobial Agents and Chemotherapy; September 27–30, 2002; San Diego, CA. Abstract 291.
   Google Scholar
• Schnell T, Schmidt B, Moschik G, et al. Distinct cross-resistance profiles of the new protease inhibitors amprenavir, lopinavir and atazanavir in a panel of clinical samples. AIDS. 2003;17:1253–1261.
   PubMed Web of Science ®Google Scholar
• Yerly S, Vora S, Günthard H, et al. Virological response following switch to atazanavir/ritonavir in relation to baseline genotypic resistance pattern. In: Program and abstracts of the XIII International HIV Drug Resistance Workshop; June 8–11, 2004; Tenerife, Spain. Abstract 149.
   Google Scholar
• Colonno R, Parkin N, McLaren C, et al. Pathways to atazanavir resistance in treatment experienced patients and impact of residue 50 substitutions. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections; February 5–11, 2004; San Fran-cisco, CA. Abstract 656.
   Google Scholar
• Sanne I, Piliero P, Squires K, et al. Results of a phase 11 clinical trial at 48 weeks: a dose ranging, safety and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naïve subjects. J Acquir Immune Defic Syndr. 2003;32:18–29.
   PubMed Web of Science ®Google Scholar
• Nieto-Cisneros L, Zala C, Fessel W, et al. Atazanavir vs lopinavir/ritonavir in patients with virologic failure to a protease inhibitor: 24-week results from BMS A1424-043. In: Program and abstracts of the Second InternationalAIDS Society Conference on HIV Pathogenesis and Treatment; July 13–16, 2003; Paris, France. Abstract 177.
   Google Scholar
• Johnson M, De Jesus E, Grinsztejn B, et al. Long-term efficacy and durability of atazanavir with ritonavir or saquinavir vs lopinavir/ritonavir in HIV-infected patients with multiple virologic failures: 96-week results from arandomized, open-label trial, BMS A1424-045. In: Pro-gram and abstracts of the Seventh International Con-gress on Drug Therapy in HIV Infection; November 14–18, 2004; Glasgow, UK. Abstract PL 14.4.
   Google Scholar
• Barrios A, RencIón A, Gallego O, et al. Predictors of virological response to atazanavir in protease inhibitor-experienced patients. HIV Clin Trials. 2004;5:201–205.
   PubMed Web of Science ®Google Scholar
• Murphy R, Sanne I, Cahn P, et al. Dose-ranging, randomised clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naïve subjects: 48-weeks re-sults. AIDS. 2003;17:2603–2614.
   PubMed Web of Science ®Google Scholar
• Squires K, Lazzarin A, Gate J, et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr. 2004;36:1011–1019.
   PubMed Web of Science ®Google Scholar
• Barreiro P, Soriano V, Casas E, González-Lahoz J. Differ-ent degree of immune recovery in HIV-infected patients receiving antiretroviral regimens containing protease in-hibitors or non-nucleosides. AIDS. 2002;16:245–249.
   PubMed Web of Science ®Google Scholar
• Manfredi R, Calza L, Chiodo F. First-line efavirenz versus lopinavir-ritonavir-based HAART for naive patients. AIDS. 2004;18:2331–2333.
   PubMed Web of Science ®Google Scholar
• Haas D, Zala C, Schrader S, et al. Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial. AIDS. 2003;17:1339–1349.
   PubMed Web of Science ®Google Scholar
• Boffito M, Kurowski M, Kruse G, et al. Atazanavir en-hances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen. AIDS. 2004;18:1291–1297.
   PubMed Web of Science ®Google Scholar
• Noor M, Grasela D, Parker R, et al. The effect of atazanavir vs lopinavir/ritonavir on insulin-stimulated glu-cose disposal rate in healthy subjects. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections; February 5–11, 2004; San Fran-cisco, CA. Abstract 702.
   Google Scholar
• Johnson M, De Jesus E, Rodriguez C, et al. Effects of baseline protease inhibitor mutations on the efficacy of ritonavir-boosted atazanavir and lopinavir/ritonavir in pa-tients who have experienced virologic failure on multiple HAART regimens In: Program and abstracts of the XIII International HIV Drug Resistance Workshop; June 8–11, 2004; Tenerife, Spain. Abstract 76.
   Google Scholar
• Wood R, Phanuphak P, Cahn P, et al. Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir. J Acquir Immune Defic Syndr. 2004;36:684–692.
   PubMed Web of Science ®Google Scholar
• Haerter G, Manfras B, Mueller M, et al. Regression of lipodystrophy in HIV-infected patients under therapy with the new protease inhibitor atazanavir. AIDS. 2004;18: 952–955.
   PubMed Web of Science ®Google Scholar
• O'Mara E, Mummaneni V, Randall D, et al. Assessment of the effect of uridine diphosphate glucuronosyltransferase 1A1 genotype on indirect bilirubin elevations in healthy subjects dosed with BMS-232632. In: Program and ab-stracts of the 40th Interscience Conference on Antimicro-bial Agents and Chemotherapy; September 2000; Toronto, Canada. Abstract 1645.
   Google Scholar
• Lloeje U, Yuan Y, L'Italien G. Protease inhibitor exposure time and risk of cardiovascular disease in HIV infected patients. In: Program and abstracts of the 11th Confer-ence on Retroviruses and Opportunistic Infections; Feb-ruary 5–11, 2004; San Francisco, CA. Abstract 736.
   Google Scholar
• Lloeje U, Wu Y, Cislo P, et al. Risk of metabolic syndrome among highly treatment-experienced HIV-infected pa-tients: 48 weeks results from BMS study Al 424045. In: Program and abstracts of the 15th International AIDS Conference; July 11–16, 2004; Bangkok, Thailand. Ab-stract WePeB5957.
   Google Scholar
• Product information. Reyataz (atazanavir). Princeton, NJ: Bristol-Myers Squibb Company; July 2004.
   Google Scholar
• Taburet A, Piketty C, Chazallon C, et al. Interactions between atazanavir-ritonavir and tenofovir in heavily pre-treated HIV-infected patients. Antimicrob Agents Chemother. 2004;48:2091–2096.
   PubMed Web of Science ®Google Scholar
• Guffanti M, De Pascalis C, Seminari E, et al. Pharmacoki-netics of amprenavir given once or twice a day when combined with atazanavir in heavily pre-treated HIV-posi-tive patients. AIDS. 2003;17:2669–2672.
   PubMed Web of Science ®Google Scholar